Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials

Abstract Aims Numerous postoperative therapies for preventing recurrence of hepatocellular carcinoma (HCC) have been reported, but their efficacy remains controversial and knowledge about adverse effects is limited. A systematic review of randomized controlled trials (RCTs) was performed to gain a c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of surgical oncology 2012-04, Vol.38 (4), p.286-295
Hauptverfasser:	Zhong, J.-H, Li, H, Li, L.-Q, You, X.-M, Zhang, Y, Zhao, Y.-N, Liu, J.-Y, Xiang, B.-D, Wu, G.-B
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - administration & dosage Adverse effects Antineoplastic Agents - administration & dosage Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - surgery Combined Modality Therapy Disease-Free Survival Hematology, Oncology and Palliative Medicine Hepatocellular carcinoma Humans Interferons - administration & dosage Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - surgery Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - surgery Overall survival Postoperative Randomized Controlled Trials as Topic Surgery Systematic review Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Aims Numerous postoperative therapies for preventing recurrence of hepatocellular carcinoma (HCC) have been reported, but their efficacy remains controversial and knowledge about adverse effects is limited. A systematic review of randomized controlled trials (RCTs) was performed to gain a comprehensive picture of the efficacy and risks of these therapies. Methods MEDLINE, EMBASE and the Cochrane Library were systematically searched through July 2011. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. Results A total of 2989 patients from 28 RCTs involving 10 postoperative therapies were included. For interferon therapy, the estimated RR for the 2-year recurrence rate was 0.84 (95% CI 0.73–0.97, P = 0.02) and the overall survival (OS) was 1.15 (95% CI 1.07–1.22, P
ISSN:	0748-7983 1532-2157
DOI:	10.1016/j.ejso.2012.01.006